Mosaic ImmunoEngineering Inc. is a pre-clinical development stage biotechnology company focused on the development and commercialization of its technology to activate the innate immune system to treat and prevent cancer and infectious diseases. The company's lead product candidate, MIE-101, is based on a naturally occurring plant virus that is non-infectious in animals and humans, but activates multiple Toll-like receptors (TLRs) through its natural immune recognition. MIE-101 naturally activates the body's innate immune system when injected into a tumor, thereby altering the tumor microenvironment and directing activated anti-tumor T cells to attack the injected tumor as well as other tumors in the body.
More about the company